AstraZeneca shares its comprehensive scientific approach at the World Conference on Lung Cancer 2017

Early-stage disease - Quality-of-life results from the Imfinzi Phase III PACIFIC trial headline the Presidential Symposium

Overcoming treatment resistance - Novel combination of Tagrisso and savolitinib provide potential new options for EGFRm patients with MET resistance

Maximising outcomes through testing - New analyses support use of blood-based testing to determine eligibility for both Tagrisso and Iressa

Potential of combinations - New data for IO combinations with and without chemotherapy in mesothelioma and NSCLC


AstraZeneca and Medimmune, its global biologics research and development arm, continue to demonstrate their progress in lung cancer research at the IASLC 18th World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan, 15-18 October 2017. With 43 data presentations, including 16 oral presentations, AstraZeneca is focusing on four key scientific drivers of progress in lung cancer: treating earlier stages of the disease; strategies to overcome tumour resistance; improved testing to match the right treatments to the right patients; and continued exploration of the potential of immuno-oncology combinations.


Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “The data we are presenting at WCLC 2017 illustrate the science-led strength of our clinical programme focused on tackling multiple mechanisms associated with this complex disease. We are constantly striving to deliver on our ambition of one day eliminating cancer as a cause of death.”


Treating lung cancer at earlier stages of the disease


To date, the majority of research has been focused on metastatic disease, where the medical need is most urgent. But with the potential for clinical benefit becoming clearer in earlier stages of disease, long-term quality of life is an increasingly important component in deciding the right treatment.


At WCLC, patient-reported outcomes from the Phase III Imfinzi PACIFIC trial will be presented during the Presidential Symposium. The PACIFIC trial of Imfinzi (durvalumab) in patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC) who have not progressed following platinum-based chemoradiation therapy, is the first to demonstrate superior progression-free survival (PFS) in this setting.


Rina Hui, MD, PhD, clinical associate professor of medicine, Westmead Clinical School at the University of Sydney and Principal Investigator on the trial, said: “As we treat patients with earlier stages of disease and pursue curative intent, quality-of-life considerations definitely affect the choice of treatment. If quality-of-life data support significant clinical benefits, then we may be looking at a new treatment paradigm for these patients.”


Overcoming tumour resistance


More patients taking therapies targeting mutations are experiencing longer periods before their disease worsens; however, tumours often adapt and develop new resistance mechanisms. At WCLC, AstraZeneca is presenting new data on novel combinations that may help overcome a common secondary resistance and established driver of disease progression in patients treated with EGFR TKIs - mesenchymal epithelial transition factor (MET).


Early safety and efficacy results from the multi-arm, Phase Ib TATTON study will be presented, investigating the c-Met receptor tyrosine kinase inhibitor (TKI) savolitinib in combination with EGFR T790M inhibitor Tagrisso (osimertinib) in patients with MET-positive resistance. [Abstract #8985]. These data will be supplemented by the first results of a multi-centre Phase Ib study investigating the combination of savolitinib and Iressa (gefitinib) in a similar patient population. [Abstract #8995].


Myung-Ju Ahn, MD, PhD, Professor, Department of Hematology & Oncology, Samsung Medical Center, Seoul, South Korea, said: “Cancer is stealthy and we must continue to find new ways to combat resistance. The early results for both gefitinib and osimertinib in combination with savolitinib show exciting progress and are an important area of continued focus.”


Testing to identify the most suitable treatment


Biomarker-guided lung cancer research is continuing to improve ways to identify patients who are most likely to benefit from treatment with precision medicines. In NSCLC, this has meant improving the accuracy and availability of blood-based testing to facilitate diagnosis and identification of the most suitable treatments throughout the disease continuum. At WCLC, AstraZeneca is presenting progress in ctDNA testing in EGFRm NSCLC across multiple lines of therapy and technologies.


In the 1st-line setting, new analyses across the Tagrisso FLAURA [Abstract #8978] and Iressa BENEFIT [Abstract #9278] trials reveal good concordance between tissue and plasma ctDNA testing, and support the utility of blood-based testing to determine eligibility for both Tagrisso and Iressa. In addition, concordance studies comparing multiple plasma ctDNA diagnostics in two different studies of Tagrisso [Abstract #8984 and #9811] in the 2nd line setting continue to build understanding of the comparability of different technologies and expand testing across platforms.


Jhanelle Gray, MD, Medical Oncologist and Director of Clinical Research in the Department of Thoracic Oncology at H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida, said: “Testing continues to be a critical part of lung cancer care, but the rapid development and evolution of multiple testing modalities and platforms can be challenging for physician teams to manage. Continued understanding of how assays compare builds confidence in treatment decisions, leading to better patient outcomes”



Combining with IO


As the promise of IO continues to build through the use of monotherapies, the next era in cancer control may involve combinations with a goal of achieving long-term survival for a broader population of patients. At WCLC, AstraZeneca is sharing results from two early trials of checkpoint inhibitor combinations, with and without chemotherapy.


·        When combined with chemotherapy, Imfinzi with or without tremelimumab could be administered safely and demonstrated encouraging preliminary clinical activity in patients with NSCLC in a study conducted by the Canadian Cancer Trials Group [Abstract #8700].


·        The Phase II, open-label, NIBIT-MESO-1 study [Abstract #9202] of Imfinzi plus tremelimumab as 1st- or 2nd-line treatment in patients with malignant mesothelioma demonstrated a safety profile consistent with our previous observations/publications in NSCLC, and clinical activity in this difficult-to-treat cancer.


Rosalyn A. Juergens MD., PhD. Assistant Professor, Department of Oncology. McMaster University, Canada said: “As we continue to explore the full benefit of immunotherapies, the promise of combinations is really starting to be seen for patients who may not be expected to benefit from the current monotherapies. We continue to push research boundaries in this area with the hope that we can make a real difference to patients in need.”


– ENDS –




Select AstraZeneca/MedImmune Presentations at WCLC 2017. For the full listing of abstracts at WCLC, please visit


Lead author

Abstract title

Presentation details

Early Stage Lung Cancer

Hui, R

Patient-reported outcomes with durvalumab after concurrent chemoradiation in Stage III unresectable NSCLC: data from PACIFIC


Presidential Symposium

Tuesday 17 October

Presentation Time: 08:15-09:45

Location: TBD

Abstract #10762


Overcoming Tumour Resistance Mechanisms

Yang, J-J

A phase Ib trial of savolitinib plus gefitinib for patients with EGFR-mutant MET-amplified advanced NSCLC


EGFR TKI Resistance

Tuesday 17 October

Presentation Time: 11:00-12:30

Location: Room 301 and 302

Abstract #8995


Anh, M-J

TATTON Phase Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI


EGFR TKI Resistance

Tuesday 17 October

Presentation Time: 11:00-12:30

Location: Room 301 and 302

Abstract #8985

Diagnostic testing in EGFRm NSCLC

Ahn, M-J

Detection of EGFR mutations from plasma ctDNA in the osimertinib Phase III trial (AURA3): comparison of three plasma assays


Liquid Biopsy for Genomic Alterations

Wednesday 18 October

Presentation Time: 11:00-12:30

Location: F201 and F202 (Annex Hall)

Abstract #8984


Wang, J

Gefitinib as first-line treatment of plasma ctDNA EGFR mutation-positive NSCLC detected by ddPCR: BENEFIT study (CTONG1405)


Emerging Diagnostics/Biomarkers in NSCLC

Tuesday 17 October

Presentation Time: 11:00-12:30

Location: Room 313 and 314

Abstract #9278


Gray, JE

Osimertinib vs SoC EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC (FLAURA): plasma ctDNA analysis


Next Generation TKI

Monday 16 October

Presentation Time: 15:45-17:30

Location: Room 301 and 302

Abstract #8978

Yokoyama, T

The usefulness of liquid biopsy for ctDNA in patients with EGFR-mutant NSCLC during and after treatment with EGFR-TKIs


Advanced NSCLC

Wednesday 18 October

Presentation Time: 9:30-16:00

Location: Exhibit Hall (Hall B and C)

Abstract #9811

IO Combinations

Juergens RA

Durvalumab ± tremelimumab with platinum-doublets in non-small cell lung cancer: Canadian Cancer Trials Group study IND.226



Tuesday 17 October

Presentation Time: 11:00-12:30

Location: Room 303 and 304

Abstract #8700

Calabro, L

Tremelimumab in combination with durvalumab in first or second-line mesothelioma patients: the NIBIT-MESO-1 study


Mesothelioma Bench to Bedside

Wednesday 18 October

Presentation Time: 11:00-12:30

Location: Room 315

Abstract #9202


About AstraZeneca in Lung Cancer

AstraZeneca is committed to developing therapies to help every patient with lung cancer. We have two approved therapies and a growing pipeline that targets genetic changes in tumour cells and boosts the power of the immune response against cancer. Our unrelenting pursuit of science aims to deliver more breakthrough therapies with the goal of extending and improving the lives of patients across all stages of disease and lines of therapy.


About AstraZeneca in Oncology

AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly growing portfolio of new medicines that has the potential to transform patients’ lives and the Company’s future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZeneca’s five Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.


By harnessing the power of four scientific platforms – Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody Drug Conjugates – and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.


About MedImmune

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology; Respiratory, Cardiovascular & Metabolic Diseases; and Infection and Vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centres, with additional sites in Cambridge, UK, and Mountain View, CA. For more information, please visit


About the WCLC

The World Conference on Lung Cancer (WCLC) is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, attracting over 6,000 researchers, physicians and specialists from more than 100 countries. The goal is to disseminate the latest scientific achievements; increase awareness, collaboration and understanding of lung cancer; and to help participants implement the latest developments across the globe. Organized under the theme of “Synergy to Conquer Lung Cancer,” the conference will cover a wide range of disciplines and unveil several research studies and clinical trial results. For more information, visit


About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.


For more information, please visit and follow us on Twitter @AstraZeneca.


Media Relations



Esra Erkal-Paler


+44 203 749 5638

Karen Birmingham


+44 203 749 5634

Rob Skelding


+44 203 749 5821

Matt Kent


+44 203 749 5906

Gonzalo Viña


+44 203 749 5916

Jacob Lund


+46 8 553 260 20

Michele Meixell


+1 302 885 2677




Investor Relations



Thomas Kudsk Larsen



+44 203 749 5712

Craig Marks

Finance, Fixed Income, M&A

+44 7881 615 764

Henry Wheeler


+44 203 749 5797

Mitchell Chan


+1 240 477 3771

Christer Gruvris

Diabetes; Autoimmunity, Neuroscience & Infection

+44 203 749 5711

Nick Stone

Respiratory; Brilinta

+44 203 749 5716

US toll free


+1 866 381 7277



  • Cancer